The Biostatistics Shared Resource Facility (BSRF) is a Markey Cancer Center (MCC)-managed resource providing comprehensive and centralized support that is readily accessible to cancer center investigators.
The specific aims of the BSRF encompass support during study planning and study conduct and at the final stage of each project. In order to achieve these aims, our services are categorized broadly into: 1) study planning, power, and sample size calculations for grant applications, clinical trials, population-based studies, and preclinical experiments;2) statistical analyses, including interim and final analysis for the entire spectrum of cancer research studies;3) statistical programming for data quality control and data processing;and 4) mentoring, teaching, and general consultation to MCC investigators. We also collaborate closely with MCC's Clinical Research and Data Management SRF, Cancer Research Informatics SRF, and other MCC shared facilities. The shared resource personnel include six faculty statisticians, two master's-level statisticians, and a faculty bioinformatician. Collectively, they have extensive cancer-specific experience, expertise, and ongoing collaborations with investigators involved in studies ranging from laboratory, in vitro, in vivo studies in mouse models of cancer, translational, and bioinformatics studies in clinical samples, clinical trials, and population-based intervention studies. BSRF personnel are highly integrated with investigators across all research programs and interact closely with other SRFs at MCC to ensure comprehensive and seamless support. With personnel who are well-versed in all aspects of the biostatistical needs of MCC investigators, the dedicated BSRF team adds significant value to the conduct of research at the MCC.
The Biostatistics Shared Resource Facility (BSRF) plays a key collaborative role in providing scientific and statistical input across the entire spectrum of cancer research being performed at the MCC. This SRF has demonstrated significant impact in the conduct of science at MCC, as evidenced by participating as co-investigators in grant applications, providing critical input in clinical trial development and trial conduct, and co-authoring with investigators in all research programs of the MCC.
|Wei, Xiaowei; Xu, Yong; Xu, Fang Fang et al. (2017) RelB Expression Determines the Differential Effects of Ascorbic Acid in Normal and Cancer Cells. Cancer Res 77:1345-1356|
|Cui, Jiajun; Xu, Wenhua; Chen, Jian et al. (2017) M2 polarization of macrophages facilitates arsenic-induced cell transformation of lung epithelial cells. Oncotarget 8:21398-21409|
|Wu, Yadi; Wang, Yu; Lin, Yiwei et al. (2017) Dub3 inhibition suppresses breast cancer invasion and metastasis by promoting Snail1 degradation. Nat Commun 8:14228|
|Wise, James T F; Wang, Lei; Zhang, Zhuo et al. (2017) The 9th Conference on Metal Toxicity and Carcinogenesis: The conference overview. Toxicol Appl Pharmacol 331:1-5|
|Carpenter, Brittany L; Liu, Jinpeng; Qi, Lei et al. (2017) Integrin ?6?4 Upregulates Amphiregulin and Epiregulin through Base Excision Repair-Mediated DNA Demethylation and Promotes Genome-wide DNA Hypomethylation. Sci Rep 7:6174|
|Jarrett, Stuart G; D'Orazio, John A (2017) Hormonal Regulation of the Repair of UV Photoproducts in Melanocytes by the Melanocortin Signaling Axis. Photochem Photobiol 93:245-258|
|Li, Liqing; Li, Xiang; Qi, Lei et al. (2017) The role of talin2 in breast cancer tumorigenesis and metastasis. Oncotarget 8:106876-106887|
|Kenlan, Dasha E; Rychahou, Piotr; Sviripa, Vitaliy M et al. (2017) Fluorinated N,N'-Diarylureas As Novel Therapeutic Agents Against Cancer Stem Cells. Mol Cancer Ther 16:831-837|
|Son, Young-Ok; Pratheeshkumar, Poyil; Divya, Sasidharan Padmaja et al. (2017) Nuclear factor erythroid 2-related factor 2 enhances carcinogenesis by suppressing apoptosis and promoting autophagy in nickel-transformed cells. J Biol Chem 292:8315-8330|
|Arnold, Susanne M; Chansky, Kari; Leggas, Markos et al. (2017) Phase 1b trial of proteasome inhibitor carfilzomib with irinotecan in lung cancer and other irinotecan-sensitive malignancies that have progressed on prior therapy (Onyx IST reference number: CAR-IST-553). Invest New Drugs 35:608-615|
Showing the most recent 10 out of 281 publications